Animal testing of retroviral-mediated gene therapy for factor VIII deficiency

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 555-561

  Greengard, Judith S ^a   Jolly, Douglas J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; COST; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSDUCTION; HEMOPHILIA A; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

EID: 0032725333     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615880     Document Type: Conference Paper

References (61)

1. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost. 1998;79:456-465.
2. Rosendaal FR, Varekamp I, Smith C, Brocker-Vriends AHJT, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TPMB, Briet E. Mortality and causes of death in Dutch hemophiliacs, 1973-1986. Br J Haematology. 1989;71:71-76.
3. Aledort LM. Some aspects on the management of hemophilia. Thromb Haemost. 1995;74:440-443.
4. Bohn RL, Avom J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of Factor VIII: an economic evaluation. Thromb Haemost. 1998;79:932-937.
5. Sawamoto Y, Prescott R, Zhong D, Saenko EL, Nauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost. 1998;79:62-68.
6. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD Jr. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 1996;88:3846-3853.
7. Connelly S and Kaleko M. Gene therapy for hemophilia A. Thromb Haemost. 1997;78:31-36.
8. Yee JK. Retroviral vectors. In: T. Friedmann, ed. The Development of Human Gene Therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999:21-45.
9. Jolly DJ. Viral vector systems for gene therapy. Cancer Gene Ther. 1994;1:51-64.
10. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet. 1994;7:362-369.
11. Simon RH, Engelhardt JF, Yang Y, Zepeda M, Weber-Pendleton S, Grossman M, Wilson JM. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther. 1993;4:771-780.
12. McCormack JE, Martineau D, DePolo N, Maifert S, Akbarian L, Townsend K, Lee W, Irwin M, Sajjadi N, Jolly DJ, Warner JF. Anti-vector immunoglobulin induced by retroviral vectors. Hum Gene Ther. 1997;8:1263-1273.
13. Bauer G, Sauter S, Ibanez C, Rice CR, Valdez P, Jolly D, Kohn DB. Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line. Biol Blood Marrow Transplant. 1998;4:119-127.
14. Human gene marker/therapy protocols. Hum Gene Ther. 1998;9:1803-1847. Editorial.
15. Vanin EF, Kaloss M, Broscius C, Nienhuis AW. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol. 1994;68:4241-4250.
16. Chuah MKL, Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther. 1995;6:1363-1377.
17. Koeberl DD, Halbert CL, Krumm A, Miller AD. Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther. 1995;6:469-479.
18. Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg DJM, van Ormondt H, Briet E, van der Eb AJ. Expression of blood clotting factor VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood. 1995;85:2447-2454.
19. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther. 1993;4:259-272.
20. Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins MK. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature. 1996;379:85-88.
21. Rigg RJ, Chen J, Dando JS, Forestell SP, Plavec I, Bohnlein E. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology. 1996;218:290-295.
22. Graham JB, Buckwalter JA, Hartley LJ, Brinkhous KM. Canine hemophilia: observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med. 1949;90:97-106.
23. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (Factor VIII:C deficiency) bleeding. Blood. 1982;60:727-732.
24. Pijnappels MI, Briet E, van der Zwet GT, Huisden R, van Tilburg NH, Eulderink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemost. 1986;55:70-73.
25. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-121.
26. Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, Giles A, Lillicrap D. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost. 1998;79:317-322.
27. Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA. Genomics. 1993;16:374-379.
28. Nakajima K, Ikenaka K, Nakahira K, Morita N, Mikoshiba K. An improved retroviral vector for assaying promoter activity. Analysis of promoter interference in pIP211 vector. FEBS Lett. 1993;315:129-133.
29. Wildner O, Candotti F, Krecko EG, Xanthopoulos KG, Ramsey WJ, Blaese RM. Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression. Gene Ther. 1998;5:684-691.
30. Valera A, Perales JC, Hatzglou M, Bosch F Expression of the neomycin-resistance (neo) gene induces alteration in gene expression and metabolism. Hum Gene Ther. 1994;5:449-456.
31. Jung D, Jaeger E, Cayeux S, Blankenstein T, Hilmes C, Karbach J, Moebius U, Knuth A, Huber C, Seliger B. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. Hum Gene Ther. 1998;9:53-62.
32. Onodera M, Yachie A, Nelson DM, Wilchin H, Morgan RA, Blaese RM. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther. 1997;8:1189-1194.
33. Tafuro S, Zentilin L, Falaschi A, Giacca M. Rapid retrovirus titration using competitive polymerase chain reaction. Gene Ther. 1996;3:679-684.
34. Greengard JS, Bodner M, McCormack J, Edwards WE, Sensintaffar JL, Hsu D, DePolo NJ, Mittlestaedt D, de la Vega Jr. DJ, Brumm D, Jolly DJ, Chang SMW. Sustained high level factor VIII antigen expression in immune-competent rabbits following peripheral intravenous injection of retroviral vector. Blood. 1996;88:273a.
35. Greengard JS, Bodner M, McCormack J, Edwards WE, Sensintaffar JL, Hsu D, DePolo NJ, Mittlestaedt D, de la Vega Jr. DJ, Brumm D, Jolly DJ, Chang SMW. Sustained high level factor VIII antigen expression in immune-competent rabbits and dogs following peripheral intravenous injection of retroviral vector. Thromb Haemost. 1997;78:3.
36. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood. 1996:87:4671-4677.
37. Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M. In vivo delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther. 1995;6:185-193.
38. Dwarki VJ, Belloni P, Nijjar T, Smith J, Cuoto L, Rabier M, Clift S, Berns A, Cohen LK. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA. 1995;92:1023-1027.
39. Connelly S, Gardner JM, McClelland A, Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther. 1996;7:183-195.
40. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997;2:3-14.
41. Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII Cell. 1998;93:61-70.
42. Hoeben RC, Einerhand MPW, Briet E, van Ormondt H, Valerio D, van der Eb AJ. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of factor VIII gene into murine haematopoeitic progenitor cells. Thromb Haemost. 1992;67:341-345.
43. Hoeben RC, Fallaux FJ, van Tilburg NH, Cramer SJ, van Ormondt H, Briet E, van der Eb AJ. Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther. 1993;4:179-186.
44. Chuah MKL, Brems H, Vanslembrouke V, Collen D, Vandendriessche T. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther. 1998;9:353-365.
45. Hurwitz DR, Kirchgesser M, Merrill W, Galanopoulos T, McGrath CA, Emami S, Hansen M, Cherington V, Appel JM, Bizinkauskas CB, Brackmann HH, Levine PH, Greenberger JS. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther. 1997;8:137-156.
46. Hurwitz DR, Cherington V, Rubin H, Wang T, Sobolewski J, Galanopoulos T, Natale A, McGrath CA, Levine PH, Greenberger JS, Chiang GG. Ex vivo gene therapy of hemophilia A and B using bone marrow stromal cells in a canine model. In: Proceedings. American Society Gene Therapy. 1998;3.
47. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA. 1998;95:5734-5739.
48. Fakharzadeh SS, Zhang Y, Sarkar R, Kazazian HH. Correction of factor VIII deficiency in a murine model for hemophilia A through transplant of factor VIII-expressing skin. Blood. 1998;92:297a.
49. Nguyen KH, Boyle DL, McCormack JE, Chada S, Jolly DJ, Firestein GS. Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis. J Rheumatol. 1998;25:1118-1125.
50. Karavodin LM, Robbins J, Chong K, Hsu D, Ibanez C, Mento S, Jolly DJ, Fong TC. Generation of a systemic antitumor immune response with regional intratumoral injections of interferon γ retroviral vector. Hum Gene Ther. 1998;9:2231-2241.
51. Warner JF, Jolly DJ, Merrit J. Human immunodeficiency virus immunotherapy using a retroviral vector. Curr Top Microbiol Immunol. 1998;226:145-160.
52. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. In vivo gene therapy of hemophilia B: sustained partial correction in Factor IX deficient dogs. Science. 1993;262:117-119.
53. Manning WC, Paliard X, Zhou S, Bland MP, Lee AY, Hong K, Walker CM, Escobedo JA, Dwarki V. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus Type 2 glycoproteins B and D. J Virol. 1993;71:7960-7962.
54. Shirley PS, Gallo AM, Andrews JL, Smith TAG, Lillicrap D, Kaleko M, Connelly S. Evaluation of adenoviral vectors for treatment of hemophilia A: demonstration of an unexpected, non-linear in vivo dose response. Blood. 1998;92:296a.
55. Mustafa RL, Elwell DL, Russell KE, Nichols TC, Read MS. A role for whole blood clotting time as a sensitive screening test for F.VIII and F.IX replacement. Blood. 1998;92:96a.
56. Littlewood JD, Barrowcliffe TW. The development and characterisation of antibodies to human Factor VIII in haemophilic dogs. Thromb Haemost. 1987;57:314-321.
57. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10:4239-4242.
58. Liu L, Xia S, Seifert J. Transplantation of spleen cells in patients with hemophilia A: a report of 20 cases. Transpl Int. 1994;7:201-206.
59. Bontempo FA, Lewis JH, Gorenc TJ, Spero JA, Ragni MV, Scott JP, Starzl TE. Liver transplantation in hemophilia A. Blood. 1987;69:1721-1724.
60. Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Bimstiel ML. In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA. 1994;91:5148-5152.
61. Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A Kaleko M. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;91:3272-3281.